KRAS and neoplasm: Our research findings support this hypothesis, and we observed that the inhibition of pan-RAF and CSF1R using SJ-C1044, a highly potent competitive inhibitor, resulted in a significant delay in tumor growth in both cell-based and mouse models harboring mutant KRAS.